Coronary interventions
Drug-coated Balloons for the Treatment of Coronary In-stent Restenosis: A Multicentre, Randomised Controlled Clinical Study November 20, 2019 | 10.4244/EIJ-D-19-00051
Showing 1-10 of 10 articles
Interventions for valvular disease
Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses July 20, 2018 | 10.4244/EIJ-D-17-00546
Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R)
December 20, 2017 | 10.4244/EIJ-D-17-00330
Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R
December 20, 2017 | 10.4244/EIJ-D-17-00291
Coronary interventions
Twelve-month results of a prospective, multicentre trial to assess the everolimus-eluting coronary stent system (PROMUS Element): the PLATINUM PLUS all-comers randomised trial January 20, 2017 | 10.4244/EIJV12I13A262
Interventions for valvular disease
Transfemoral aortic valve implantation with the repositionable Lotus valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience August 20, 2016 | 10.4244/EIJV12I6A124
Coronary interventions
Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial June 10, 2016 | 10.4244/EIJV12I2A30
Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds
June 19, 2015 | 10.4244/EIJY14M12_10